持续3%盐水输注联合7.5%高渗盐水团注与重型颅脑损伤患者死亡率降低相关:单中心回顾性队列研究
该单中心回顾性队列纳入993例接受7.5%高渗盐水治疗的神经重症患者,其中重型颅脑损伤(GCS 3-9)亚组212例。联合治疗组(7.5%团注+持续3%输注,n=142)相比单用团注组(n=851),在IPTW调整后与更低的ICU死亡率(16.2% vs 41.1%;调整OR 0.23,95%CI 0.08-0.65,p=0.006)和28天死亡率(18.9% vs 45.7%;调整OR 0.20,95%CI 0.07-0.55,p=0.002)相关,五项敏感性分析一致。总体队列中趋势有利但未达显著,联合组总钠负荷更高却峰值血钠更低且ICP控制更优。作者强调为观察性研究,需前瞻性验证后方可临床采用。
要点
- 重型颅脑损伤(GCS 3-9)亚组中,联合治疗与ICU死亡率显著降低相关(16.2% vs 41.1%;调整OR 0.23,95%CI 0.08-0.65,p=0.006)。
- 同亚组28天死亡率联合组亦显著更低(18.9% vs 45.7%;调整OR 0.20,95%CI 0.07-0.55,p=0.002),五项敏感性分析结果一致。
- 总体队列中联合治疗趋势有利但未达显著(ICU死亡率OR 0.58,p=0.121;28天死亡率OR 0.59,p=0.110),Kaplan-Meier总生存获益显著(log-rank p=0.006)。
- 联合组总钠负荷更高,但峰值血钠更低且ICP控制更优,提示持续渗透梯度而非峰值血钠可能驱动获益。
- 原文明确为观察性研究,IPTW调整及高E值仍不能完全排除适应证混杂,临床采用前需前瞻性验证。
适用人群与场景
- 韩国某三级学术医院神经重症患者,接受7.5%高渗盐水团注治疗者;主要分析聚焦重型颅脑损伤亚组(GCS 3-9,n=212)。
- 联合治疗组为7.5%团注+持续3%盐水输注(n=142),单用团注组为仅7.5%团注(n=851)。
- 原文未提及明确的排除标准或具体急诊/ICU/院前场景划分。
诊断标准与关键阈值
- 重型颅脑损伤定义:Glasgow Coma Scale(GCS)3-9分。
- 原文未提及其他诊断标准、评分界值或启动/停止阈值。
处置流程与药物剂量
- 原文未提及具体药物剂量(7.5%团注量、3%输注速率)、给药途径细节、频次、疗程或目标血钠值。
- 联合治疗定义为7.5%高渗盐水团注加持续3%盐水输注;单用团注定义为仅7.5%高渗盐水团注。
- 原文提及联合组总钠负荷更高但峰值血钠更低、ICP控制更优,未给出具体数值。
红旗征与不能漏的情况
- 原文未提及具体红旗征或需要立即处理/不能漏诊的情况。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究,韩国三级学术医院,993例接受7.5%高渗盐水治疗的神经重症患者;采用IPTW调整混杂,五项敏感性分析(含多重插补和E值评估)。
- 重型颅脑损伤亚组(GCS 3-9,n=212):联合治疗vs单用团注,ICU死亡率16.2% vs 41.1%(调整OR 0.23,95%CI 0.08-0.65,p=0.006);28天死亡率18.9% vs 45.7%(调整OR 0.20,95%CI 0.07-0.55,p=0.002)。
- 总体队列:联合治疗趋势有利但未达显著(ICU死亡率OR 0.58,p=0.121;28天死亡率OR 0.59,p=0.110);Kaplan-Meier总生存获益显著(log-rank p=0.006)。
- 联合组总钠负荷更高,但峰值血钠更低且ICP控制更优。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究;原文未给出正式证据等级或推荐强度。
- 局限:观察性设计,尽管IPTW调整及高E值,适应证混杂不能完全排除,需前瞻性验证后方可临床采用;原文明确建议谨慎解读。
对床旁实践的改变
- 原文提示在重型颅脑损伤(GCS 3-9)患者中,7.5%高渗盐水团注联合持续3%盐水输注可能与更低死亡率相关,但因观察性设计且需前瞻性验证,原文明确不主张在临床采用前据此改变实践。
- 原文强调持续渗透梯度而非峰值血钠可能驱动获益,联合组总钠负荷更高但峰值血钠更低,提示监测峰值血钠并非唯一目标。
- 原文未提及适用/不适用人群的排除标准或常见陷阱。
指南或共识出处
- 原文未提及指南或共识名称;来源为Neurocrit Care发表的单中心回顾性队列研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bolus hypertonic saline (HTS) is a cornerstone for managing intracranial hypertension, yet its transient effect mandates repeated dosing and may induce wide sodium fluctuations. Whether augmenting bolus 7.5% HTS with continuous 3% saline infusion to sustain osmotic gradients improves outcomes in neurocritical patients remains unknown.
METHODS: We conducted a retrospective cohort study of 993 neurocritical patients treated with 7.5% HTS at a tertiary academic hospital in South Korea. Patients were classified as bolus-alone (n = 851) or combined therapy (7.5% bolus plus 3% continuous infusion; n = 142). The primary analysis focused on patients with severe brain injury (Glasgow Coma Scale [GCS] 3-9; n = 212). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. Robustness was confirmed through five sensitivity analyses, including multiple imputations and E-value assessment for unmeasured confounding.
RESULTS: In the severe brain injury subgroup, combined therapy was associated with markedly lower ICU mortality (16.2% vs. 41.1%; adjusted odds ratio [OR] 0.23, 95% CI 0.08-0.65, p = 0.006) and 28-day mortality (18.9% vs. 45.7%; adjusted OR 0.20, 95% CI 0.07-0.55, p = 0.002). All five sensitivity analyses consistently confirmed these findings. In the overall cohort, trends favored combined therapy but did not reach significance (ICU mortality: OR 0.58, p = 0.121; 28-day mortality: OR 0.59, p = 0.110), although time-to-event analysis showed a significant overall survival benefit (Kaplan-Meier log-rank p = 0.006). Strikingly, despite a greater total sodium load, the combined group achieved lower peak serum sodium yet superior ICP control, suggesting that sustained osmotic gradients-not peak sodium-drive the benefit.
CONCLUSIONS: In patients with severe brain injury, combined 7.5% HTS bolus and 3% continuous saline infusion was associated with substantially lower mortality compared with bolus therapy alone. These findings support further prospective investigation of combination osmotic therapy in neurocritical care. These observational findings should be interpreted with caution; despite IPTW adjustment and high E-values, confounding by indication cannot be fully excluded, and prospective validation is required before clinical adoption.
参考来源
- Choi HW, Ryu JA. Continuous 3% Saline Infusion Combined with 7.5% Hypertonic Saline Bolus is Associated with Lower Mortality in Patients with Severe Brain Injury: A Single-Center Retrospective Cohort Study. Neurocrit Care. 2026. PMID: 42601563. doi:10.1007/s12028-026-02632-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。